Emi Caywood, MD

Subburaj, D., Ng, B., Kariminia, A., Abdossamadi, S., Lauener, M., Nemecek, E. R., & Schultz, K. R. (2022). Metabolomic identification of alpha-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. Blood, 139(2), 287-299. doi:10.1182/blood.2021013244

Getz, K. D., Szymczak, J. E., Li, Y., Madding, R., Huang, Y.-S. V., Aftandilian, C., & Aplenc, R. (2021). Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 4(10). doi:10.1001/jamanetworkopen.2021.28385

Schultz, K. R., Kariminia, A., Ng, B., Abdossamadi, S., Lauener, M., Nemecek, E. R., & Cuvelier, G. D. E. (2020). Immune profile differences between chronic GVHD and late acute GVHD: Results of the ABLE/PBMTC 1202 studies. Blood, 135(15), 1287-1298. doi:10.1182/BLOOD.2019003186

Chan, A. Y., Leiding, J. W., Liu, X., Logan, B. R., Burroughs, L. M., Allenspach, E. J., & Torgerson, T. R. (2020). Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 11. doi:10.3389/fimmu.2020.00239

Dvorak, C. C., Haddad, E., Buckley, R. H., Cowan, M. J., Logan, B., Griffith, L. M., & Puck, J. M. (2019). The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). Journal of Allergy and Clinical Immunology, 143(1), 405-407. doi:10.1016/j.jaci.2018.08.027

Cuvelier, G. D. E., Nemecek, E. R., Wahlstrom, J. T., Kitko, C. L., Lewis, V. A., Schechter, T., & Schultz, K. R. (2019). Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood, 134(3), 304-316. doi:10.1182/blood.2019000216

Shields, C. L., Say, E. A. T., Pefkianaki, M., Regillo, C. D., Caywood, E. H., Jabbour, P. M., & Shields, J. A. (2017). RHEGMATOGENOUS RETINAL DETACHMENT after INTRAARTERIAL CHEMOTHERAPY for RETINOBLASTOMA: The 2016 Founders Award Lecture. Retina, 37(8), 1441-1450. doi:10.1097/IAE.0000000000001382

Shields, C. L., Alset, A. E., Say, E. A. T., Caywood, E., Jabbour, P., & Shields, J. A. (2016). Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era. Journal of Pediatric Ophthalmology and Strabismus, 53(5), 275-284. doi:10.3928/01913913-20160719-04

Shields, C. L., Jorge, R., Say, E. A. T., Magrath, G., Alset, A., Caywood, E., & Shields, J. A. (2016). Unilateral retinoblastoma managed with intravenous chemotherapy versus intra-arterial chemotherapy. Outcomes based on the international classification of retinoblastoma. Asia-Pacific Journal of Ophthalmology, 5(2), 97-103. doi:10.1097/APO.0000000000000172

Lewen, M., Gresh, R., Queenan, M., Paessler, M., Pillai, V., Hexner, E., & Wertheim, G. (2016). Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: A case report. Biomarker Research, 4(1). doi:10.1186/s40364-016-0069-0

Caywood, E. H., & Kolb, E. A. (2015). Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials. Journal of Clinical Oncology, 33(36), 4238-4239. doi:10.1200/JCO.2015.63.9252

Hossain, M. J., Xie, L., & Caywood, E. H. (2015). Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data. Cancer Epidemiology, 39(5), 720-726. doi:10.1016/j.canep.2015.06.009